- Home
- PLL vs SCLXW Comparison
PLL vs SCLXW Comparison
Compare PLL & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLL
- SCLXW
- Stock Information
- Founded
- PLL 2016
- SCLXW N/A
- Country
- PLL United States
- SCLXW United States
- Employees
- PLL N/A
- SCLXW 115
- Industry
- PLL Other Metals and Minerals
- SCLXW Biotechnology: Pharmaceutical Preparations
- Sector
- PLL Basic Materials
- SCLXW Health Care
- Exchange
- PLL Nasdaq
- SCLXW Nasdaq
- Market Cap
- PLL N/A
- SCLXW N/A
- IPO Year
- PLL 2017
- SCLXW N/A
- Fundamental
- Price
- PLL $6.18
- SCLXW $0.09
- Analyst Decision
- PLL Hold
- SCLXW
- Analyst Count
- PLL 6
- SCLXW 0
- Target Price
- PLL $11.92
- SCLXW N/A
- AVG Volume (30 Days)
- PLL 182.0K
- SCLXW 4.0K
- Earning Date
- PLL 05-07-2025
- SCLXW 03-07-2025
- Dividend Yield
- PLL N/A
- SCLXW N/A
- EPS Growth
- PLL N/A
- SCLXW N/A
- EPS
- PLL N/A
- SCLXW N/A
- Revenue
- PLL $106,472,000.00
- SCLXW $55,152,000.00
- Revenue This Year
- PLL $0.39
- SCLXW N/A
- Revenue Next Year
- PLL $31.17
- SCLXW N/A
- P/E Ratio
- PLL N/A
- SCLXW N/A
- Revenue Growth
- PLL 100.07
- SCLXW 22.02
- 52 Week Low
- PLL $5.15
- SCLXW $0.18
- 52 Week High
- PLL $15.44
- SCLXW $0.18
- Technical
- Relative Strength Index (RSI)
- PLL 38.22
- SCLXW N/A
- Support Level
- PLL $6.20
- SCLXW N/A
- Resistance Level
- PLL $6.60
- SCLXW N/A
- Average True Range (ATR)
- PLL 0.30
- SCLXW 0.00
- MACD
- PLL -0.06
- SCLXW 0.00
- Stochastic Oscillator
- PLL 4.36
- SCLXW 0.00
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.